A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
Melissa PalmerLee JenningsDebra G SilbergCaleb BlissPatrick MartinPublished in: BMC pharmacology & toxicology (2018)
ClinicalTrials.gov identifier: NCT02287779 (registration first received 6 November 2014).